Satralizumab 是一种人源化单克隆抗体，是一种有效的白细胞介素 -6 (IL-6) 抑制剂。Satralizumab 可防止褐家鼠的 dTAA 形成和发展。Satralizumab 可用于视神经脊髓炎 (NMOSD) 和降胸主动脉动脉瘤 (dTAA) 的研究。
| Cas No. | 1535963-91-7 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Satralizumab, a humanized monoclonal antibody, is a potentInterleukine-6 (IL-6)inhibitor. Satralizumab prevents dTAA formation and progression in rattusnorvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2]. Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattusnorvegicus[1]. | Animal Model: | Rattusnorvegicus(forty, male, 10-week-old, four equal groups)[1] | | Dosage: | 120 mg | | Administration: | Subcutaneously, once every 2 weeks, for 4 weeks | | Result: | Prevented dTAA (descending thoracic aorta aneurysm) formation and progression. |
|
